Ethical approval granted to conduct CAR-T cell immune therapy clinical trial
Researchers granted ethical approval to conduct a phase 1 clinical trial to investigate CAR-T cell immune therapy as a treatment for Diffuse Midline Glioma, a devastating paediatric brain tumour
Supported by funds from the NRF, Dr Tessa Gargett and Professor Michael Brown from the Centre for Cancer Biology have been able to show that this treatment, where a patient’s own white blood cells are extracted and genetically engineered to seek and destroy cancer cells, is extremely effective at killing DMG cells in the lab.
We are excited to announce that this proof-of-principle study provided enough evidence that the team, together with their collaborator Associate Professor David Ziegler, were recently granted Human Research Ethics Committee (HREC) approval to conduct a phase 1 clinical trial at Sydney Children’s Hospital, with the CAR-T cell manufacturing to be performed right here in Adelaide!
This essential step will allow the trial to open in the coming months so stay tuned.
The trial is now registered with the Australian and New Zealand Clinical Trials Registry so that patients and doctors can find out more information, and apply to be enrolled once the trial is open: anzctr.org.au/Trial/Registration/TrialReview.aspx?id=383497&isReview=true
This world-leading research would not be possible without the support of our donors. Every donation helps, with 100% going straight to research.
Donate to Grey May and join the fight against brain tumours: www.nrf.com.au/go-grey-in-may
